Annals of Clinical and Translational Neurology
Clinical Impact of MGMT Promoter Methylation in IDH ‐Mutant Gliomas: Influence of Threshold Selection and Clinical Confounding
ABSTRACT Background The clinical relevance of MGMT promoter methylation in IDH‐mutant gliomas remains controversial in the era of molecular classification. We aimed to systematically evaluate its clinical relevance by integrating quantitative assessment, cutoff exploration, and adjustment for clinical confounding. Methods A total of 558 patients with WHO grade 2–3 IDH‐mutant gliomas were retrospectively analyzed. MGMT promoter methylation was quantified by pyrosequencing. Survival outcomes were assessed using Kapla …